Title Page
Title: Feasibility of Therapeutic Drug Monitoring of Sunitinib
and its implications on response and toxicity in patients with
metastatic renal cell cancer.
Short Title: Feasibility of sunitinib TDM in renal cancer
Khushboo Gandhia,1 , Amit Joshic,d,1, Parsshava Mehtaa , Murari Gurjara, Pallavi Raneb , Jyoti Sharmaa ,
Anand Patila,d , Manjunath
Nookalaa,d , Vanita Noronhac,d ,
Kumar Prabhashc,d., Vikram Gota*a,d
1: Authors contributed equally to the present work
aDepartment of Clinical Pharmacology, Advanced Centre
for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial
Centre (TMC), Kharghar, Navi Mumbai-410210, India.
bDepartment of Biostatistics, Advanced Centre for
Treatment, Research and Education in Cancer (ACTREC), Tata Memorial
Centre (TMC), Kharghar, Navi Mumbai-410210, India.
cDepartment of Medical Oncology, Tata Memorial
Hospital, Parel, Mumbai-400012, India.
dHomi bhabha National Institute, Mumbai-400094, India
*To whom correspondence should be addressed: Dr. Vikram Gota, Advanced
Centre for Treatment, Research and Education in Cancer (ACTREC), Tata
Memorial Centre (TMC), Sector-22, Kharghar, Navi Mumbai-410210, India,
Tel.: +91-22-27405493; Fax: +91-22-27405085; E-mail:
vgota76@actrec.gov.in
Principal Investigator statement : The authors confirm that the
Principal Investigator for this paper is Dr. Vikram Gota and that he had
direct clinical responsibility for patients.
Key Words: Sunitinib; Therapeutic Drug Monitoring; Objective
response; SU12662; Toxicity
Word count of text: 1727
Table Count: 1
Figure Count: 2